Mesoblast Limited (ASX:MSB)
1.575
-0.015 (-0.94%)
Jul 9, 2025, 4:10 PM AEST
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
125.51K AUD
Profits / Employee
-2.29M AUD
Market Cap
2.01B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CSL Limited | 32,698 |
Cochlear | 5,097 |
Sonic Healthcare | 42,000 |
Ramsay Health Care | 90,000 |
Telix Pharmaceuticals | 234 |
Ansell | 15,000 |
Regis Healthcare | 11,000 |
Neuren Pharmaceuticals | 8 |
Mesoblast News
- 2 days ago - Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade) - Seeking Alpha
- 8 days ago - Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday - Benzinga
- 8 days ago - Mesoblast, FDA agree on marketing application for cell therapy - Seeking Alpha
- 8 days ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 8 days ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 8 days ago - Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure - GlobeNewsWire
- 27 days ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 7 weeks ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire